Meeting
2020 ASCO Virtual Scientific Program
A phase I/II study of eribulin mesilate (ERI) plus irinotecan (IRI) in children with refractory or recurrent solid tumors.
Authors
Michela Casanova
Fondazione IRCCS Istituto Nazionale Tumori, Milan, Italy
Michela Casanova , Christof Kramm , Dirk Reinhardt , Franco Locatelli , David R. D'Adamo , Rachael Scott , Yan Jia , Jagadeesh Aluri , Claudio Favre , Francisco Bautista , Raquel Hladun Alvaro , Ana Sastre Urgelles , Udo Kontny
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Pediatric Oncology
Track
Pediatric Oncology
Sub Track
Pediatric Solid Tumors
Clinical Trial Registration Number
NCT03245450
Citation
J Clin Oncol 38: 2020 (suppl; abstr 10535)
DOI
10.1200/JCO.2020.38.15_suppl.10535
Abstract #
10535
Poster Bd #
422
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
A pilot clinical study of oral irinotecan HCl (VAL-413) in patients with recurrent pediatric solid tumors.
First Author: Jeffrey A. Bacha
First Author: Stuart Cramer
Poster
2016 ASCO Annual Meeting
A phase 1 study of eribulin mesylate (E7389), a novel microtubule targeting chemotherapeutic agent in children with refractory or recurrent solid tumors (excluding CNS), including lymphomas: a Children’s Oncology Group Phase 1 Consortium study (ADVL1314).
First Author: Eric Schafer
Poster
2022 ASCO Annual Meeting
A pilot clinical study of VAL-413 (oral irinotecan HCl) in patients with recurrent pediatric solid tumors.
First Author: Dennis Brown